Medical care and treatment of allergic rhinitis. A population-based cohort study based on routine healthcare utilization data.

Related Articles

Medical care and treatment of allergic rhinitis. A population-based cohort study based on routine healthcare utilization data.

Allergy. 2016 Jan 8;

Authors: Schmitt J, Stadler E, Küster D, Wüstenberg EG

Abstract
BACKGROUND: Health services research on medical care and treatment of allergic rhinitis (AR) is scarce.
OBJECTIVES: To investigate the prevalence, incidence, comorbidities, and treatment of AR in a realistic setting.
METHODS: A cohort of 1,811,094 German National Health Insurance beneficiaries in 2005 was followed until 2011. To avoid misclassification, the ICD-10-code for AR (J30) had to be documented at least twice to classify patients as having AR. Descriptive statistics and logistic regression models were used to describe the burden, comorbidities, and treatment of AR.
RESULTS: A total of 111,394 patients (6.2%) had prevalent AR in 2005/2006. In another 60,145 individuals (3.3%) AR was newly diagnosed in 2007 to 2011 (incident cases). Patients with prevalent AR were three times more likely to develop asthma compared to patients without AR (age and sex-adjusted risk ratio (RR) 3.04; 95% confidence interval (95%CI) 2.98 – 3.10). Newly diagnosed recurrent depressive disorder (RR 1.61; 95%CI 1.55 – 1.68), anxiety disorder (RR 1.52; 95%CI 1.48 – 1.56) and ADHD (RR 1.21; 95%CI 1.13 – 1.29) were also related to prevalent AR. Approximately 20% of children and 36% of adults with AR were exclusively treated by general practitioners. Allergy immunotherapy (AIT) was prescribed for 16.4% of AR patients. Subcutaneous immunotherapy was most frequently used (80% of AIT).
CONCLUSIONS: This study highlights the significant burden of AR. Despite the established benefits of AIT to treat AR and prevent asthma this study suggests significant undertreatment. Future research is necessary to develop and implement adequate measures to increase guideline adherence. This article is protected by copyright. All rights reserved.

PMID: 26749452 [PubMed – as supplied by publisher]

View full post on pubmed: asthma

Current and future biomarkers in allergic asthma.

Related Articles

Current and future biomarkers in allergic asthma.

Allergy. 2015 Dec 25;

Authors: Zissler UM, Bieren JE, Jakwerth CA, Chaker AM, Schmidt-Weber CB

Abstract
Diagnosis early in life, sensitization, asthma endotypes, monitoring of disease and treatment progression are key motivations for the exploration of biomarkers for allergic rhinitis and allergic asthma. The number of genes related to allergic rhinitis and allergic asthma increases steadily, however prognostic genes have not yet entered clinical application. We hypothesize that the combination of multiple genes may generate biomarkers with prognostic potential. The current review attempts to group more than 161 different potential biomarkers involved in respiratory inflammation to pave the way for future classifiers. The potential biomarkers are categorized into either epithelial or infiltrate-derived or mixed origin, epithelial biomarkers. Furthermore surface markers were grouped into cell-type specific categories. The current literature provides multiple biomarkers for potential asthma endotypes that are related to T cell phenotypes such as Th1, Th2, Th9, Th17, Th22 and Tregs and their lead cytokines. Eosinophilic and neutrophilic asthma endotypes are also classified by epithelium-derived CCL-26 and osteopontin, respectively. There are currently about 20 epithelium-derived biomarkers exclusively derived from epithelium, which are likely to innovate biomarker panels as they are easy to sample. This article systematically reviews and categorizes genes and collects current evidence that may promote these biomarkers to become part of allergic rhinitis or allergic asthma classifiers with high prognostic value. This article is protected by copyright. All rights reserved.

PMID: 26706728 [PubMed – as supplied by publisher]

View full post on pubmed: asthma

Omalizumab Highly Effective for Severe Allergic Asthma – Monthly Prescribing Reference (registration)

Omalizumab Highly Effective for Severe Allergic Asthma
Monthly Prescribing Reference (registration)
Ivo Abraham, PhD, RN, from the University of Arizona in Tucson, and colleagues reviewed 24 real-life effectiveness studies of omalizumab in the treatment of severe allergic asthma. The studies included 4,117 unique patients from 32 countries

View full post on asthma – Google News

Allergic Asthma – Pipeline Review, H2 2015 Market Analysis,Competitive … – Medgadget.com (blog)

Allergic Asthma – Pipeline Review, H2 2015 Market Analysis,Competitive
Medgadget.com (blog)
This report provides comprehensive information on the therapeutic development for Allergic Asthma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA

and more »

View full post on asthma – Google News

A Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK-Abello A/S, Originator or ALK HDM Tablets in Adult Subjects With Allergic Rhinitis and/or Atopic Asthma Induced by House Dust Mites (HDM)

Conditions:   Allergy;   Asthma;   Rhinitis
Interventions:   Drug: Mitizax;   Drug: Placebo
Sponsors:   Abbott;   Linical Co., Ltd;   Datamap
Recruiting – verified November 2015

View full post on ClinicalTrials.gov: asthma | received in the last 14 days

A Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK-Abello A/S, Originator or ALK HDM Tablets (ALK HDM Tablets) in Adult Subjects With Allergic Rhinitis and/or Atopic Asthma Induced by House Dust Mites (HDM)

Conditions:   Allergy;   Asthma;   Rhinitis
Interventions:   Drug: Mitizax;   Drug: Placebo
Sponsors:   Abbott;   Linical Co., Ltd;   Datamap
Recruiting – verified November 2015

View full post on ClinicalTrials.gov: asthma | received in the last 14 days

Can Food Allergies Put You at a Higher Risk of Developing Asthma? – Allergic Living

Can Food Allergies Put You at a Higher Risk of Developing Asthma?
Allergic Living
Q: My 6-year-old son has food allergies and now also seems to be coughing a lot during the night (long after he's eaten). Could he be developing asthma? How can we know and what are the next steps? Dr. Bassett: You are right to be concerned. A history

and more »

View full post on asthma – Google News

Allergic asthma: UFZ researchers identify a key molecule – EurekAlert (press release)

Allergic asthma: UFZ researchers identify a key molecule
EurekAlert (press release)
Worldwide, there are more than 300 million asthma patients. In Germany alone, 10 – 15 percent of children suffer from allergic asthma that is often impaired by environ-mental pollutants. With the medications available today, symptoms can be effectively …

and more »

View full post on asthma – Google News